Two Phase 2 Trials to Assess Production of Dystrophin in Patients with Nonsense Mutation Duchenne Muscular Dystrophy Receiving Ataluren

被引:0
|
作者
Nelson, S.
Penematsa, V
Chou, C.
Trifillis, P.
Bibbiani, F.
McIntosh, J.
机构
关键词
Neuromuscular Disorders; Rare Diseases;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
186
引用
收藏
页码:S127 / S127
页数:1
相关论文
共 50 条
  • [1] Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
    Finkel, Richard S.
    Flanigan, Kevin M.
    Wong, Brenda
    Boennemann, Carsten
    Sampson, Jacinda
    Sweeney, H. Lee
    Reha, Allen
    Northcutt, Valerie J.
    Elfring, Gary
    Barth, Jay
    Peltz, Stuart W.
    PLOS ONE, 2013, 8 (12):
  • [3] Demographics of patients with nonsense mutation Duchenne muscular dystrophy receiving ataluren in the STRIDE Registry
    Muntoni, F.
    Mercuri, E.
    Buccella, F.
    Desguerre, I.
    Kirschner, J.
    Nascimento Osorio, A.
    Tulinius, M.
    Jiang, J.
    Kristensen, A.
    Johnson, S.
    Able, R.
    Trifillis, P.
    Santos, C.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S62 - S62
  • [4] Safety and Tolerability of Ataluren in a Phase 3 Study of Patients with Nonsense Mutation Duchenne Muscular Dystrophy
    Campbell, Craig
    Shieh, Perry
    Sejersen, Thomas
    Luo, Xiaohui
    Elfring, Gary
    Kroger, Hans
    Riebling, Peter
    Ong, Tuyen
    Spiegel, Robert
    Peltz, Stuart
    Wong, Brenda
    NEUROLOGY, 2016, 86
  • [5] Meta-analyses of ataluren in patients with nonsense mutation Duchenne muscular dystrophy
    Muntoni, F.
    Mercuri, E.
    Luo, X.
    Elfring, G.
    Werner, C.
    Trifillis, R.
    Peltz, S. W.
    McDonald, C. M.
    NEUROMUSCULAR DISORDERS, 2018, 28 : S12 - S12
  • [6] Meta-Analyses of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
    Campbell, C.
    Muntoni, F.
    Mercuri, E.
    Luo, X.
    Elfring, G.
    Kroger, H.
    Riebling, P.
    Ong, T.
    Spiegel, R.
    Peltz, S.
    McDonald, C.
    ANNALS OF NEUROLOGY, 2016, 80 : S365 - S365
  • [7] Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy
    Campbell, Craig
    Barohn, Richard J.
    Bertini, Enrico
    Chabrol, Brigitte
    Comi, Giacomo Pietro
    Darras, Basil T.
    Finkel, Richard S.
    Flanigan, Kevin M.
    Goemans, Nathalie
    Iannaccone, Susan T.
    Jones, Kristi J.
    Kirschner, Janbernd
    Mah, Jean K.
    Mathews, Katherine D.
    McDonald, Craig M.
    Mercuri, Eugenio
    Nevo, Yoram
    Pereon, Yann
    Ben Renfroe, J.
    Ryan, Monique M.
    Sampson, Jacinda B.
    Schara, Ulrike
    Sejersen, Thomas
    Selby, Kathryn
    Tulinius, Mar
    Vilchez, Juan J.
    Voit, Thomas
    Wei, Lee-Jen
    Wong, Brenda L.
    Elfring, Gary
    Souza, Marcio
    McIntosh, Joseph
    Trifillis, Panayiota
    Peltz, Stuart W.
    Muntoni, Francesco
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (14) : 973 - 984
  • [8] META-ANALYSES OF ATALUREN IN PATIENTS WITH NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY (NMDMD)
    Butterfield, Russell J.
    Luo, Xiaohui
    Elfring, Gary
    Kroger, Hans
    Riebling, Peter
    McIntosh, Joseph
    Ong, Tuyen
    Spiegel, Robert
    Peltz, Stuart W.
    McDonald, Craig
    MUSCLE & NERVE, 2016, 54 : 12 - 13
  • [9] Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene - evaluation through a managed access agreement
    Ayyar-Gupta, V.
    Ridout, D.
    Manzur, A.
    Muntoni, F.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S167 - S167
  • [10] Updated demographics and safety data from patients with nonsense mutation Duchenne muscular dystrophy receiving ataluren in the STRIDE Registry
    Muntoni, F.
    Buccella, F.
    Desguerre, I.
    Kirschner, J.
    Mercuri, E.
    Osorio, A. Nascimento
    Tulinius, M.
    Johnson, S.
    Werner, C.
    Kristensen, A.
    Jiang, J.
    Li, J.
    Trifillis, P.
    Santos, C.
    NEUROMUSCULAR DISORDERS, 2021, 31 : S91 - S92